vs
哈雷戴维森（HOG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是哈雷戴维森的2.0倍（$772.1M vs $390.5M），Revvity净利率更高（12.7% vs -72.3%，领先85.1%），Revvity同比增速更快（5.9% vs -9.4%），Revvity自由现金流更多（$161.8M vs $100.4M），过去两年Revvity的营收复合增速更高（9.0% vs -48.6%）
哈雷戴维森是源自美国的摩托车制造商与生活方式品牌，总部位于威斯康星州密尔沃基，创立于1903年。它是大萧条时期幸存下来的两大美国摩托车厂商之一，历经多次股权变动、子公司调整、经营困境与全球竞争，如今已是全球知名的标志性品牌。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HOG vs RVTY — 直观对比
营收规模更大
RVTY
是对方的2.0倍
$390.5M
营收增速更快
RVTY
高出15.2%
-9.4%
净利率更高
RVTY
高出85.1%
-72.3%
自由现金流更多
RVTY
多$61.4M
$100.4M
两年增速更快
RVTY
近两年复合增速
-48.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $390.5M | $772.1M |
| 净利润 | $-282.6M | $98.4M |
| 毛利率 | -7.9% | — |
| 营业利润率 | -92.4% | 14.5% |
| 净利率 | -72.3% | 12.7% |
| 营收同比 | -9.4% | 5.9% |
| 净利润同比 | -138.6% | 3.9% |
| 每股收益（稀释后） | $-2.27 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOGRVTY
| Q4 25 | $390.5M | $772.1M | ||
| Q3 25 | $1.1B | $698.9M | ||
| Q2 25 | $1.0B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $430.9M | $729.4M | ||
| Q3 24 | $881.2M | $684.0M | ||
| Q2 24 | $1.4B | $691.7M | ||
| Q1 24 | $1.5B | $649.9M |
净利润HOGRVTY
| Q4 25 | $-282.6M | $98.4M | ||
| Q3 25 | $377.4M | $46.7M | ||
| Q2 25 | $107.6M | $53.9M | ||
| Q1 25 | $133.1M | $42.2M | ||
| Q4 24 | $-118.4M | $94.6M | ||
| Q3 24 | $119.0M | $94.4M | ||
| Q2 24 | $218.3M | $55.4M | ||
| Q1 24 | $234.9M | $26.0M |
毛利率HOGRVTY
| Q4 25 | -7.9% | — | ||
| Q3 25 | 26.0% | 53.6% | ||
| Q2 25 | 28.5% | 54.5% | ||
| Q1 25 | 28.9% | 56.5% | ||
| Q4 24 | -2.0% | — | ||
| Q3 24 | 29.8% | 56.3% | ||
| Q2 24 | 31.8% | 55.7% | ||
| Q1 24 | 30.9% | 54.6% |
营业利润率HOGRVTY
| Q4 25 | -92.4% | 14.5% | ||
| Q3 25 | 44.0% | 11.7% | ||
| Q2 25 | 10.7% | 12.6% | ||
| Q1 25 | 14.8% | 10.9% | ||
| Q4 24 | -44.9% | 16.3% | ||
| Q3 24 | 12.0% | 14.3% | ||
| Q2 24 | 17.8% | 12.4% | ||
| Q1 24 | 17.8% | 6.8% |
净利率HOGRVTY
| Q4 25 | -72.3% | 12.7% | ||
| Q3 25 | 35.0% | 6.7% | ||
| Q2 25 | 10.2% | 7.5% | ||
| Q1 25 | 12.3% | 6.4% | ||
| Q4 24 | -27.5% | 13.0% | ||
| Q3 24 | 13.5% | 13.8% | ||
| Q2 24 | 16.1% | 8.0% | ||
| Q1 24 | 15.9% | 4.0% |
每股收益（稀释后）HOGRVTY
| Q4 25 | $-2.27 | $0.86 | ||
| Q3 25 | $3.10 | $0.40 | ||
| Q2 25 | $0.88 | $0.46 | ||
| Q1 25 | $1.07 | $0.35 | ||
| Q4 24 | $-0.82 | $0.77 | ||
| Q3 24 | $0.91 | $0.77 | ||
| Q2 24 | $1.63 | $0.45 | ||
| Q1 24 | $1.72 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.1B | $919.9M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $3.1B | $7.3B |
| 总资产 | $8.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资HOGRVTY
| Q4 25 | $3.1B | $919.9M | ||
| Q3 25 | $1.8B | $931.4M | ||
| Q2 25 | $1.6B | $991.8M | ||
| Q1 25 | $1.9B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $2.2B | $1.2B | ||
| Q2 24 | $1.8B | $2.0B | ||
| Q1 24 | $1.5B | $1.7B |
总债务HOGRVTY
| Q4 25 | $2.5B | — | ||
| Q3 25 | $4.5B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $7.3B | — | ||
| Q2 24 | $7.0B | — | ||
| Q1 24 | $6.3B | — |
股东权益HOGRVTY
| Q4 25 | $3.1B | $7.3B | ||
| Q3 25 | $3.6B | $7.4B | ||
| Q2 25 | $3.3B | $7.6B | ||
| Q1 25 | $3.2B | $7.6B | ||
| Q4 24 | $3.2B | $7.7B | ||
| Q3 24 | $3.4B | $7.9B | ||
| Q2 24 | $3.4B | $7.9B | ||
| Q1 24 | $3.3B | $7.8B |
总资产HOGRVTY
| Q4 25 | $8.0B | $12.2B | ||
| Q3 25 | $10.6B | $12.1B | ||
| Q2 25 | $12.1B | $12.4B | ||
| Q1 25 | $12.4B | $12.4B | ||
| Q4 24 | $11.9B | $12.4B | ||
| Q3 24 | $13.0B | $12.8B | ||
| Q2 24 | $12.8B | $13.4B | ||
| Q1 24 | $12.3B | $13.4B |
负债/权益比HOGRVTY
| Q4 25 | 0.79× | — | ||
| Q3 25 | 1.25× | — | ||
| Q2 25 | 1.91× | — | ||
| Q1 25 | 2.14× | — | ||
| Q4 24 | 2.00× | — | ||
| Q3 24 | 2.13× | — | ||
| Q2 24 | 2.03× | — | ||
| Q1 24 | 1.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $152.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $100.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 25.7% | 21.0% |
| 资本支出强度资本支出/营收 | 13.2% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $415.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HOGRVTY
| Q4 25 | $152.0M | $182.0M | ||
| Q3 25 | $-92.6M | $138.5M | ||
| Q2 25 | $368.0M | $134.3M | ||
| Q1 25 | $141.5M | $128.2M | ||
| Q4 24 | $133.2M | $174.2M | ||
| Q3 24 | $353.0M | $147.9M | ||
| Q2 24 | $473.6M | $158.6M | ||
| Q1 24 | $104.0M | $147.6M |
自由现金流HOGRVTY
| Q4 25 | $100.4M | $161.8M | ||
| Q3 25 | $-129.1M | $120.0M | ||
| Q2 25 | $332.4M | $115.5M | ||
| Q1 25 | $111.6M | $112.2M | ||
| Q4 24 | $77.0M | $149.8M | ||
| Q3 24 | $300.4M | $125.6M | ||
| Q2 24 | $432.2M | $136.6M | ||
| Q1 24 | $57.6M | $129.7M |
自由现金流率HOGRVTY
| Q4 25 | 25.7% | 21.0% | ||
| Q3 25 | -12.0% | 17.2% | ||
| Q2 25 | 31.7% | 16.0% | ||
| Q1 25 | 10.3% | 16.9% | ||
| Q4 24 | 17.9% | 20.5% | ||
| Q3 24 | 34.1% | 18.4% | ||
| Q2 24 | 31.9% | 19.7% | ||
| Q1 24 | 3.9% | 20.0% |
资本支出强度HOGRVTY
| Q4 25 | 13.2% | 2.6% | ||
| Q3 25 | 3.4% | 2.6% | ||
| Q2 25 | 3.4% | 2.6% | ||
| Q1 25 | 2.8% | 2.4% | ||
| Q4 24 | 13.0% | 3.4% | ||
| Q3 24 | 6.0% | 3.3% | ||
| Q2 24 | 3.1% | 3.2% | ||
| Q1 24 | 3.1% | 2.7% |
现金转化率HOGRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | -0.25× | 2.97× | ||
| Q2 25 | 3.42× | 2.49× | ||
| Q1 25 | 1.06× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 2.97× | 1.57× | ||
| Q2 24 | 2.17× | 2.87× | ||
| Q1 24 | 0.44× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOG
| Motorcycles | $193.9M | 50% |
| Other | $63.8M | 16% |
| Other Income Financial Services | $59.8M | 15% |
| Apparel | $47.2M | 12% |
| Livewire Segment | $11.4M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
